,i #aahth ,,congress #ast ,session ,h4 ,r4 #fgij ,,in ,,the ,,house ,,of ,,representatives ,december #ad1 #bjbc,mr4 ,bilirakis 7for himself and ,ms4 ,sewell7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend the ,public ,health ,service ,act with respect to preventing end-stage kidney disease1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,new ,era of ,preventing ,end-,stage ,kidney ,disease ,act4 #b4 ,centers of ,excellence on ,rare ,kidney ,disease ,research in ,national ,institute of ,diabetes and ,digestive and ,kidney ,diseases ,subpart #c of part ,c of title ,,iv of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bha et seq47 is amended by inserting after section #dbf 7#db ,u4,s4,c4 #bhe;c7 the following new section3 #dbf;,a4 ,centers of ,excellence on ,rare ,kidney ,disease ,research in ,national ,institute of ,diabetes and ,digestive and ,kidney ,diseases 7a7 ,cooperative agreements and grants 7#a7 ,in general ,the ,director of the ,institute may enter into cooperative agreements with1 and make grants to1 public and private nonprofit entities to pay all or part of the cost of planning1 establishing1 or strengthening1 and providing basic operating support for1 regional centers of excellence for rare kidney diseases1 including primary glomerular disease4 ,such centers of excellence shall be known as ,,niddk ,centers of ,excellence on ,rare ,kidney ,disease ,research 7referred to in this section as ,centers of ,excellence74 7#b7 ,purposes of centers ,the purposes of the ,centers of ,excellence funded pursuant to paragraph 7#a7 shall be-- 7,a7 to conduct research on the causes1 etiology1 symptoms1 diagnosis1 progression1 and treatment of rare kidney diseases1 including glomerular diseases2 7,b7 to increase public awareness of rare kidney diseases1 particularly in rural and underserved communities2 and 7,c7 to develop resources for clinical research into1 training in1 and demonstration of diagnostic1 prevention1 control1 and treatment methods for1 rare kidney diseases4 7#c7 ,policies ,a cooperative agreement or grant under paragraph 7#a7 shall be entered into in accordance with policies established by the ,director of the ,national ,institutes of ,health4 7b7 ,coordination with other institutes ,the ,director of the ,institute shall coordinate the activities under this section with similar activities that are related to rare kidney disease and conducted by other national research institutes1 centers1 and agencies of the ,national ,institutes of ,health and by the ,food and ,drug ,administration4 7c7 ,use of funds ,an entity that enters into a cooperative agreement or receives a grant under subsection 7a7 may use funds received through such agreement or grant-- 7#a7 to cover patient care costs required to conduct research described in subsection 7a77#b77;,a72 7#b7 to provide1 for the purpose described in subsection 7a77#b77;,b7-- 7,a7 clinical training and continuing education for health professionals and related personnel with respect to rare kidney diseases2 and 7,b7 information programs for the public1 with respect to rare kidney diseases2 and 7#c7 to provide1 for the purpose described in subsection 7a77#b77;,b7-- 7,a7 for education of members of the public1 particularly through outreach to rural and underserved communities1 on the diagnosis 7including through routine urinalysis and through genetic testing71 prevention1 control1 and treatment of rare kidney diseases2 and 7,b7 for education of individuals diagnosed with rare kidney diseases on renal diet and lifestyle1 genetic testing1 and programs to promote urinalysis1 and on mental and emotional health resources for families of rare kidney disease patients4 7d7 ,research funded ,research conducted using funds awarded through a cooperative agreement or grant under this section-- 7#a7 shall include study of genotype-phenotype relation to disease progression2 and 7#b7 with respect the populations studied in such research1 may not include any consideration of quality-adjusted life years or disability adjusted life years1 or other similar mechanisms that discriminate against individuals with disabilities in value and cost-effectiveness assessments4 7e7 ,period of support2 additional periods ,the period of support for a center of excellence under subsection 7a7 may not exceed #e years1 except that such period may be extended by the ,director of the ,institute for additional periods of not more than #e years for each center if-- 7#a7 the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the ,director of the ,institute2 and 7#b7 such group has recommended to the ,director of the ,institute that such period should be extended4 7f7 ,authorization of appropriations ,to carry out this section1 there are authorized to be appropriated #f1jjj1jjj for each of fiscal years #bjbd through #bjbh4 4 #c4 ,understanding and ,slowing the ,progression of ,rare ,kidney ,disease ,through ,early ,intervention1 ,testing1 and ,treatment 7a7 ,in general ,the ,secretary shall conduct a study on testing1 preventative care1 precision medicine1 and treatment1 with respect to rare kidney disease4 ,such study shall review-- 7#a7 the impact of routine urinalysis on the timely diagnosis of rare kidney disease and on the quality of patient care following a diagnosis of such disease2 7#b7 the quality and reliability of kidney biopsy in the diagnosis of rare kidney disease2 7#c7 the utility and appropriate use of genetic and genomic tests in detecting kidney disease1 including-- 7,a7 advances in genetic and genomic testing1 and in particular testing of the ,,apol#a gene1 and whether such testing may improve the diagnosis and treatment of rare kidney disease2 7,b7 barriers to genetic and genomic testing1 such as diagnostic1 predictive1 presymptomatic testing1 and ,,dna sequencing clinical services1 including an analysis of any existing barriers related to health insurance coverage of such testing and access to genetic counselors1 pathologists1 and other relevant professions2 and 7,c7 strategies to increase routine urinalysis and other diagnostic testing and to improve technologies to diagnose such disease1 including genetic testing1 and to improve access to health insurance coverage of such diagnostic testing and technologies2 7#d7 the social1 behavioral1 and biological factors leading to rare kidney disease2 7#e7 treatment patterns associated with providing care1 under the ,medicare program under title ,,xviii of the ,social ,security ,act 7#db ,u4,s4,c4 #acie et seq471 the ,medicaid program under title ,,xix of such ,act 7#db ,u4,s4,c4 #acif et seq471 and through private health insurance1 to populations that are disproportionately affected by such disease2 7#f7 access to nephrologists among populations that are disproportionately affected by such disease2 7#g7 ongoing efforts and recommendations to slow the progression of end-stage kidney disease in populations that are disproportionately affected by rare kidney disease2 and 7#h7 patient trust of treating providers among populations that are disproportionately affected by such disease4 7b7 ,report 7#a7 ,in general ,not later than #ah months after the date of the enactment of this ,act1 the ,secretary shall submit to the ,congress a report on the results of the study under subsection 7a71 together with such recommendations as the ,secretary determines to be appropriate4 7#b7 ,consultation ,in conducting the study under subsection 7a7 and developing the report required by paragraph 7#a71 the ,secretary shall consult with relevant stakeholders1 including health care providers1 medical professional societies1 ,state-based societies1 public health experts1 health educators1 health professional organizations1 drug and device manufacturers1 patient organizations1 pharmacists1 payors1 ,state and local public health departments1 ,state medical boards1 and other entities with experience in health care1 public health1 nephrology1 and rare disease1 as appropriate4 7c7 ,coordination ,in carrying out the activities under subsections 7a7 and 7b71 the ,secretary shall coordinate with the ,director of ,,nih1 the ,administrator of the ,center for ,medicare ,medicaid ,services1 the ,administrator of the ,health ,resources and ,services ,administration1 and the ,director of the ,center for ,medicare and ,medicaid ,innovation4 7d7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #a1jjj1jjj for each of fiscal years #bjbd through #bjbh4 #d4 ,provider education 7a7 ,primary care training ,section #gdg7;b77#c77;,e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bick7b77#c77;,e77 is amended-- 7#a7 by striking and individuals and inserting 1 individuals2 and 7#b7 by inserting 1 and individuals with kidney disease 7including rare kidney disease7 after disabilities4 7b7 ,nephrology fellowships ,section #gcf7;b7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bic7 is amended-- 7#a7 by redesignating paragraph 7#g7 as paragraph 7#h72 7#b7 in paragraph 7#f77;,b71 by striking 2 and and inserting a semicolon2 and 7#c7 by inserting after paragraph 7#f7 the following3 7#g7 to award fellowships1 which may include stipends1 for postgraduate training in the field of nephrology1 for the purposes of-- 7,a7 increasing providers' knowledge of issues related to prevention1 diagnosis1 and treatment of rare kidney disease for populations disproportionately impacted by the disease1 including the prevalence of the gene ,,apol#a2 7,b7 improving the quality of rare kidney disease prevention1 diagnosis1 and treatment delivered to racial and ethnic minorities2 and 7,c7 increasing the number of nephrologists trained to provide care to such populations2 and 4 #e4 ,delaying kidney disease impact ,section #ahha7;f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acierr7f77 is amended by adding at the end the following new paragraph3 7#i7 7,a7 ,the ,secretary shall conduct experiments to evaluate methods for treating rare kidney disease1 giving particular attention to treatments that would delay or eliminate the need for dialysis and transplant4 7,b7 ,the ,secretary shall conduct a comprehensive study of methods to increase public awareness of rare kidney disease4 7,c7 ,the ,secretary shall submit to ,congress1 not later than #bd months after the date of the enactment of the ,new ,era of ,preventing ,end-,stage ,kidney ,disease ,act1 a report on the experiments and study conducted under subparagraphs 7,a7 and 7,b74 ,such report shall include recommendations for legislative changes that the ,secretary finds necessary or desirable as a result of such experiments and study4 4